(Q36835826)

16 August 2017

1 reference

title

Drug metabolite profiling and elucidation of drug-induced hepatotoxicity (English)

1 reference

16 August 2017

1 reference

Wei Tang

1

1 reference

PubMed ID

17539747

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

16 August 2017

1 reference

16 August 2017

3

1 reference

16 August 2017

407-420

1 reference

16 August 2017

3

1 reference

Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Covalent binding of 2-phenylpropionyl-S-acyl-CoA thioester to tissue proteins in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Drug-related hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

The Treatment of Acetaminophen Poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

The molecular toxicology of acetaminophen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Intracellular signaling mechanisms of acetaminophen-induced liver cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Genomics and proteomics analysis of acetaminophen toxicity in mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Role of innate immunity in acetaminophen-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Paracetamol Overdosage Pharmacological Considerations and Clinical Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Diclofenac-associated hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Fatal hepatitis associated with diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

The metabolism of diclofenac--enzymology and toxicology perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Biotransformation of Diclofenac Sodium (Voltaren®) in Animals and in Man.: II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Incorporation of an oxygen from water into troglitazone quinone by cytochrome P450 and myeloperoxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Mechanisms of troglitazone hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Reye's syndrome: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Reye's syndrome in the United States from 1981 through 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Clinical pharmacokinetics of the salicylates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Pharmacokinetics of Salicylate in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Serum salicylate concentrations in Reye's disease. A study of 130 biopsy-proven cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Valproic acid hepatic fatalities: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Valproic acid hepatic fatalities. II. US experience since 1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Mitochondrial metabolism of valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

The role of carnitine supplementation during valproic acid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Children versus adults: pharmacokinetic and adverse-effect differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Molecular mechanisms of cholestasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Hepatobiliary transporters and drug-induced cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Clinical pharmacokinetics of terbinafine (Lamisil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Immunochemical detection of flucloxacillin adduct formation in livers of treated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

The role of pathology in the identification of drug-induced hepatic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Mechanisms of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Ito cells are liver-resident antigen-presenting cells for activating T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Minimising the potential for metabolic activation in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Metabonomic modeling of drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

A proteomic investigation of drug-induced steatosis in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Paracelsus: herald of modern toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Pharmaco-metabonomic phenotyping and personalized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

Molecular mechanisms of the hepatotoxicity caused by acetaminophen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.407

21 January 2018

Identifiers

DOI

10.1517/17425255.3.3.407

1 reference

16 August 2017

1 reference

PubMed ID

17539747